You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson

Last Updated: July 7, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,598,119

Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,598,119 protect, and when does it expire?

Patent 8,598,119 protects CAPLYTA and is included in one NDA.

This patent has sixteen patent family members in nine countries.

Summary for Patent: 8,598,119
Title:Methods and compositions for sleep disorders and other disorders
Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.
Inventor(s): Mates; Sharon (New York, NY), Fienberg; Allen (New York, NY), Wennogle; Lawrence (New York, NY)
Assignee: Intra-Cellular Therapies, Inc. (NY)
Application Number:12/994,560
Patent Claim Types:
see list of patent claims

Recent additions to Drugs Protected by US Patent 8,598,119

These patents are from the daily update and have not yet been integrated into the regular database
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Product Substance Delist Req. Patent Expiration Usecode Patented / Exclusive Use
Intra-cellular CAPLYTA lumateperone tosylate CAPSULE 209500 Dec 20, 2019 RX Yes   Start Trial   Start Trial U-543 TREATMENT OF SCHIZOPHRENIA
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Type >RLD >Patent No. >Product >Substance >Delist Req. >Patent Expiration >Usecode >Patented / Exclusive Use

Drugs Protected by US Patent 8,598,119

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Intra-cellular CAPLYTA lumateperone tosylate CAPSULE;ORAL 209500-001 Dec 20, 2019 RX Yes Yes   Start Trial   Start Trial TREATMENT OF SCHIZOPHRENIA   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,598,119

PCT Information
PCT FiledMay 27, 2009PCT Application Number:PCT/US2009/003261
PCT Publication Date:December 03, 2009PCT Publication Number: WO2009/145900

International Family Members for US Patent 8,598,119

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2009251816   Start Trial
Australia 2015218433   Start Trial
Canada 2725342   Start Trial
China 102105059   Start Trial
China 105168219   Start Trial
European Patent Office 2320731   Start Trial
European Patent Office 3085231   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.